Juárez HÚ

Language: Spanish
References: 12
Page: 79-83
PDF size: 69.07 Kb.

ABSTRACT

At the present time non-ST elevation acute coronary syndromes are the most important cause of hospital admissions. Troponin determination in clinical practice is a key element of diagnosis, risk evaluation and prognosis, and now, defines the population that will benefit from IIb/IIIa inhibitors treatment. Probably a “universal standard value of Troponins” is needed to uniform our therapeutic criteria. The “minor elevations” for troponin-I are considered ‹ 0.4 ng/dL and 0.5 ng/dL for troponin-T. The treatment of non ST elevation acute myocardial infarction with IIb/IIIa inhibitors may reduce the total amount of troponins and myocardial damage.

REFERENCES

1. Braunwald E, Antman E, Beasley J, Califf R, Melvin CH, Hochman J, et al: ACC/AHA Guidelines for the management of patients with unstable angina and non ST elevation myocardial infarction. JACC 2000; 36: 970-1072.

2. Keith AF: Acute Syndromes presentation clinical spectrum and management. Heart 2000; 84: 93-100.

3. Juárez U, Trejo W, Whente M, Contreras G, Cárdenas M, Reyes P: Utilidad de la determinación de mioglobina, isoenzima MB de creatina fosfocinasa, dehidrogenasa láctica y aspartatoaminotransferasa en el diagnóstico de infarto agudo del miocardio. Arch Inst Cardiol Mex 1998; 68: 214-217.

4. Boersma E, Harrington R, White H: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. A metaanalysis of major randomized clinical trials. Lancet 2002; 359: 189.198.

5. Juárez U, Lasses A, Rosas M, Luna J, Lopez MC, Chuquiure E, et al: Utilidad de la determinación cualitativa rápida de troponina T, fracción MB de creatinafosfocinasa y mioglobina en los syndromes coronarios agudos. Arch Inst Cardiol Mex 1998; 68: 473-481.

6. Antman EM, Tanasijevic MJ, Thompson B: Cardiac Specific troponin I levels to predict he risk of mortality in patients with acute coronary síndromes. N Engl J Med 1996; 335: 1342-49.

7. Ham CW, Heeschen C, Goldman B, Vahanian A, Agedy J, Macaya C, et al: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. CAPTURE study investigators. N Engl J Med 1999; 340: 1623-1629.

8. PRISM Study Investigators: Platelet receptor inhibition in ischemic syndrome management . A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-1505.

9. Canon CP, Weintrub WS, Demopuolos LA, Vicari R, Martin F, Lakkis N, et al: Comparison of early invasive and conservative strategies implement with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor-tirofiban. N Engl J Med 2001; 344: 1879-1887.

10. Morrow DA, Cannon CP, Rifai N, Martin J, Ralph V, Nasser L, et al: Ability of minor elevations of troponins to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: Results from a randomized trial. JAMA 2001; 286: 2405-2412.

11. Boersma E, Akkerhuis KM, Theroux P, Califf R, Topol E, Simoons ML, et al: Platelet IIb/IIIa receptor inhibition in non-ST elevation acute coronary syndromes :early benefit during medical treatment only, with additional protection during percutaneus coronary intervention. Circulation 1999; 100: 2045-2048.

12. Januzzi JL, Hanh S, Chae C, Giuliano R, Lewandrowski K, Theroux P, et al: Effect of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. Am J Cardiol 2000; 86: 713-717.